FDA Approves Amneal's Prednisolone Acetate Ophthalmic Suspension - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Amneal's Prednisolone Acetate Ophthalmic Suspension

Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.

  • By

  • mdspire news news staff

  • June 13, 2025

  • 1 min

Share

  • 1

    Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension, 1% sterile.

  • 2

    The product references Pred Forte, a trademark of Allergan, Inc., an AbbVie company.

  • 3

    The launch of prednisolone acetate ophthalmic suspension is planned for the third quarter of 2025.

  • 4

    This ophthalmic suspension is indicated for treating steroid-responsive ocular inflammation.

  • 5

    Common adverse reactions include elevated intraocular pressure, possible glaucoma, and delayed wound healing.

Original Source(s)

FDA Approves Amneal's Prednisolone Acetate Ophthalmic Suspension

  • by mdspire news news staff

  • June 13, 2025

Related Content

Approaching Uveitic Retinal Detachments

Uveitis Corner: Careful control of inflammation, thoughtful surgical planning, and vigilant postoperative management can help optimize outcomes in these complex cases.

A Novel Technique for Uveitis

Dr. David Chin Yee describes the benefits of delivering XIPERE directly into the suprachoroidal space

Association between social vulnerability index and cataract surgery care in medicare beneficiaries: a retrospective cohort study